Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors

Breast Cancer Research and Treatment

Volumn 40, Issue 2, 1996, Pages 129-139

  Szepeshazi, Karoly ^a   Schally, Andrew V ^a,b   Halmos, Gabor ^a   Szoke, Balazs ^a   Groot, Kate ^a   Nagy, Attila ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AgNOR; Apoptosis; Cytotoxic compounds; EGF receptors; Experimental breast cancer; LH RH agonist; Organ distribution

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; GONADORELIN; GONADORELIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CYTOTOXICITY; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0029789916     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806208     Document Type: Article

References (45)

1. Sondik J: Breast cancer trends. Incidence, mortality, and survival. Cancer 74: 995-999, 1994
2. Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocr Rev 11: 221-265, 1990
3. Robinson SP, Jordan VC: Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49: 1758-1762, 1989
4. Noguchi M, Tajiri K, Taniya T, Kumaki.T, Ashikari A, Miyazaki I: Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7). Oncology 47: 19-24, 1990
5. Fendl C, Zimniski SJ: Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res 52: 235-237, 1992
6. Schally AV, Comaru-Schally AM, Hollander V: Hypothalamic and other peptide hormones. Chapter XVII-3. In: Holland JF, Frei E, Bast EC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer Medicine, 3rd edition. Philadelphia PA, Lea & Febiger, 1993, pp 827-840
7. Emons G, Schally AV: The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Human Reprod 9: 1364-1379, 1994
8. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 131: 231-233, 1985
9. Foekens JA, Klijn JGM: Direct antitumor effects of LH-RH analogs. Rec Results Cancer Res 124: 7-17, 1992
10. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV: Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 21: 181-192, 1992
11. Eidne KA, Flanagan CA, Harris NS, Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425-432, 1987
12. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137-147, 1989
13. Srkalovic G, Szende B, Redding TW, Groot K, Schally AV: Receptors for D-Trp-6-luteinizing hormone-releasing hormone, somatostatin and insulin-like growth factor I in MXT mouse mammary carcinoma. Proc Soc Exp Biol Med 192: 209-218, 1989
14. Vincze B, Palyi I, Daubner D, Kremmer T, Szamel I, Bodrogi I, Sugar J, Seprodi J, Mezo I, Taplan I et al.: Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts. J Steroid Biochem Mol Biol 38: 119-126, 1991
15. Carbone PR Nixon DW, Fennelly J, Greenberg E, Renderson IC, Hortobagyi G, Kennedy BJ, Trainin N, Scanlon EF: Adjuvant systemic therapy. Cancer 65: 2108-2109, 1990
16. Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FI: Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. Cancer 65: 200-206, 1990
17. Bonadonna G: From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992. Int J Cancer 55: 1-4, 1993
18. Schally AV: Hypothalamic hormones: from neuroendocrinology to cancer therapy. Anti-Cancer Drugs 5: 115-130, 1994
19. Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV: Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. Proc Natl Acad Sci USA 86: 6318-6322, 1989
20. Bajusz S, Janaky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, Redding TW, Schally AV: Highly potent metallo-peptide analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86: 6313-6317, 1989
21. Janaky T, Juhasz A, Bajusz S, Csernus V Srkalovic G, Bokser L, Redding TW, Nagy A, Schally AV: Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proc Natl Acad Sci USA 89: 972-976, 1992
22. Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T: Effect of LH-RH analogs containing cytotoxic radicals on growth of estrogen independent MXT mouse mammary carcinoma in vivo. Anti-Cancer Drugs 3: 109-116, 1992
23. Pinski J, Schally AV, Yano T, Szepeshazi K, Halmos G, Groot K, Comaru-Schally AM, Radulovic S, Nagy A: Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate 23: 165-178, 1993
24. Szoke B, Horvath J, Halmos G, Rekasi Z, Groot K, Nagy A, Schally AV: LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro. Peptides 15: 359-366, 1994
25. Szepeshazi K, Schally AV, Halmos G, Groot K, Radulovic S: Antagonist of bombesin/GRP releasing peptide inhibits growth of estrogen dependent and independent MXT mammary cancer in mice. J Natl Cancer Inst 84: 1915-1922, 1992
26. Halmos G, Wittliff JL, Schally AV: Characterization of bombesin/GRP receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 53: 280-287, 1995
27. Munson PJ, Rodbard S: LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220-239, 1980
28. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV: Inhibition of growth of MCF-7 Mill human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat 21: 35-45, 1992
29. Mullen P, Scott WN, Miller WR: Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 63: 930-932, 1991
30. Milovanovic SR, Monje E, Szepeshazi K, Radulovic S, Schally A: Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing hormone-releasing hormone in MXT mouse mammary carcinoma. J Cancer Res Clin Oncol 119: 273-278, 1993
31. Sainsbury JR, Farndon JR, Sherbet GV et al.: Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1: 364-366, 1985
32. Formento JL, Francoual M, Formento P, Etienne MC, Fischel JL, Namer M, Frenay M, François E, Milano G: Epidermal growth factor receptor assay: Validation of a single point method and application to breast cancer. Breast Cancer Res Treat 17: 211-219, 1990
33. Osborne CK: Regulation of breast cancer growth by steroid hormones and growth factors: Clinical implications. Cancer Bull 45: 483-488, 1993
34. Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, Blarney RW, Ellis IO: Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43: 970-976, 1990
35. Gasparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, Sainsbury JRC: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66: 970-976, 1992
36. 2+ mobilizing hormones: The case of gonadotropin-releasing hormone. Endocrine Rev 11: 326-353, 1990
37. Ewing TM, Murphy LJ, Ng ML, Pang GYN, Lee CSL, Watts KW, Sutherland RL: Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer 44: 744-752, 1989
38. Gregory H, Thomas CE, Willshire IR, Yorg JA, Anderson H, Baildam A, Howell A. Epidermal and transforming growth factor a in patients with breast tumors. Br J Cancer 59: 605-609, 1989
39. Guazzoni L, Perego P, Banfi P, Zunino F: Modulation of epi-dermal growth factor receptor tyrosine phosphorylation by tumor necrosis factor. Cancer Lett 57: 103-108, 1991
40. Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV: Inhibitory effect of bombesin/gastrin releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 Mill human breast cancer xenografts in athymic nude mice. Cancer 73: 1229-1238, 1994
41. Shirahige Y, Cai R-Z, Szepeshazi K, Halmos G, Pinski J, Groot K, Schally AV: Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. Biomed & Pharmacother 48: 465-472, 1994
42. Hanauske A-R, Osborne CK, Chamness GC, Clark GM, Forseth BJ, Buchok JB, Arteaga CL, von Hoff DD: Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol 23: 545-551, 1987
43. Miller WR: Prognostic factors in breast cancer. Br J Cancer 66: 775-776, 1992
44. Derenzini M, Trere D: Importance of interphase nucleolar organizer regions in tumor pathology. Virchows Arch B Cell Pathol 61: 1-8, 1991
45. Szepeshazi K, Korkut E, Schally AV: Decrease in AgNOR number in Dunning R3327 prostate cancer after treatment with LH-RH agonist and antagonist. Am J Pathol 138: 1273-1277, 1991